BrainChild Bio完成1.16亿美元A轮融资，核心用途是推进B7-H3靶向自体CAR-T BCB-276进入DIPG关键性II期ILLUMINATE注册试验，同时推进三靶点CAR-T BCB-214进入胶质母细胞瘤临床开发。 BCB-276源于西雅图儿童医院多年CNS CAR-T研究，其一期试验21名治疗患者从确诊起中位生存期达到19.8个月，相较DIPG约11个月的历史生存水平显示出较强信号。新II期预计入组约75人，采用单臂、外部历史对照，并以总生存期为主要终点。公司同时拥有FDA突破性疗法及RMAT资格，因此目前已从科研型项目进入真正的注册和商业化验证阶段。有问题，问星光智能体！人类基地：AI越来越像人，而我们正在越来越像AI 投资亮点 BrainChild Bio本轮1.16亿美元A轮融资的核心意义，不只是获得充足资金，而是公司已跨过多个早期生物科技项目的关键去风险节点。核心资产BCB-276已有较完整人体临床基础：BrainChild-03一期共治疗21名DIPG患者，累计完成253次脑室内CAR-T输注，从确诊起中位总生存期达19.8个月，且有少数长期生存者。相较DIPG历史中位生存约11个月，这一结果具有较强概念验证价值。一、该数据仍需谨慎解读。一期为单中心、非随机研究，且患者治疗时点并不一致，存在患者选择和基线差异，因此不能简单认为BCB-276已将生存期从11个月延长至近20个月。真正决定项目价值的是关键性II期ILLUMINATE能否复制这一生存优势。二、监管方面，BCB-276已获得FDA突破性疗法和RMAT资格。 ILLUMINATE计划入组约75名患者，以总生存期为主要终点，并采用外部历史对照。对于罕见且高度致死的儿童脑瘤，这种设计可降低样本量和开发时间，但外部对照的可比性也是核心风险。如果OS改善幅度足够大，注册路径可能较顺畅；若仅改善数月，则统计和监管解释难度将明显增加。三、科学上，BCB-276的差异化在于脑室内局部、重复给药。该策略可部分绕开血脑屏障，提高CAR-T到达肿瘤的机会，并通过多次输注维持暴露。如果这一模式得到验证，其价值可能不仅限于DIPG，而是形成CNS肿瘤CAR-T平台。后续BCB-214同时靶向EGFR、B7-H3和IL13Rα2，试图解决实体瘤抗原异质性和抗原逃逸问题。四、商业化则是主要结构性挑战。美国DIPG每年仅约300例，单一适应症市场有限，而且自体细胞制造、脑内导管植入及多次输注会提高治疗成本和运营复杂度。因此，DIPG更像是平台验证入口，而真正决定公司长期估值上限的，是能否进一步进入胶质母细胞瘤等更大市场。综合看，这是一笔风险较高但质量较好的生物科技融资。Bull case是ILLUMINATE显著改善OS并推动BLA，同时验证CNS局部CAR-T平台；Bear case则是一期疗效无法复制、外部对照受到质疑，以及复杂给药方式限制商业化。未来最值得关注的是ILLUMINATE的入组速度、安全性、治疗完成率，以及OS曲线能否形成持续的长期生存尾部。整体判断偏积极，但真正的价值拐点仍取决于II期临床结果。注：以上为投资研究框架，不构成个人投资建议 BrainChild的价值分析 BrainChild Bio是一家专注于中枢神经系统（CNS）肿瘤CAR-T疗法的临床阶段生物科技公司，其核心战略是以儿童脑瘤DIPG作为临床突破口，验证“局部递送+多靶点+功能增强”的CAR-T平台，再向胶质母细胞瘤（GBM）及脑转移等更大适应症扩展。一、产品优势核心资产BCB-276是一款靶向B7-H3的自体CAR-T，已进入DIPG关键性II期ILLUMINATE研究，并获得FDA突破性疗法、RMAT等监管资格，临床成熟度较高。下一代产品BCB-214同时靶向EGFR、B7-H3和IL13Rα2，旨在降低脑肿瘤因抗原异质性导致的治疗逃逸。二、技术优势公司采用脑室内局部递送，使CAR-T直接进入脑脊液和肿瘤区域，在一定程度上绕开血脑屏障，并通过重复输注维持治疗暴露。相比传统静脉CAR-T，该模式有望提高脑肿瘤局部药效，同时减少全身暴露和相关毒性。公司还结合多靶点设计和CAR-T功能增强技术，提高细胞在免疫抑制肿瘤微环境中的持续活性。三、平台优势 BrainChild Bio并非单一资产公司，而是围绕EGFR、HER2、B7-H3、IL13Rα2等多个脑肿瘤靶点建立CAR-T技术体系，并承接西雅图儿童医院多年CNS CAR-T研发与临床经验。一旦BCB-276验证成功，其递送、制造、多靶点和功能增强技术有望快速复用于其他脑肿瘤。四、服务与商业模式公司本质上属于创新药研发企业，而非医疗服务公司，目前主要通过临床试验提供在研治疗。未来商业模式预计以自主开发CAR-T产品、获得监管批准并商业化为主，同时可能通过授权合作和适应症扩展放大平台价值。由于自体CAR-T涉及个体化制造、脑室导管植入及多次给药，未来商业化成本和运营复杂度仍是重要挑战。五、医疗价值 DIPG是一种高度致死且治疗选择极少的儿童脑瘤，因此BCB-276具有显著未满足医疗需求价值。更重要的是，DIPG可以作为技术验证入口；若平台进一步进入GBM及脑转移市场，潜在患者规模和商业空间将明显扩大。 BrainChild Bio的核心竞争力在于CNS专用CAR-T平台、局部重复递送、多靶点设计和功能增强技术的组合。若ILLUMINATE证实明确生存获益，公司不仅可能建立BCB-276的产品价值，也可能显著提升整个CNS CAR-T平台的估值。主要风险仍包括临床疗效能否复制、自体制造成本、复杂给药方式以及未来在GBM等竞争市场中的有效性和可商业化程度。局部脑内CAR-T BrainChild Bio的科学核心可以概括为：通过局部重复递送、多靶点识别和功能增强三层设计，解决CAR-T治疗中枢神经系统实体瘤的三个主要障碍——进入肿瘤、识别异质肿瘤、在免疫抑制环境中持续发挥作用。第一，局部脑室内给药是其最重要的技术基础。传统静脉CAR-T进入脑组织受血脑屏障限制，而且大量细胞暴露于全身，可能增加毒性。 BrainChild采用脑室内（ICV）给药，让CAR-T直接进入脑脊液，通过脑脊液循环接触肿瘤，同时可每2—4周重复输注。理论优势是提高局部细胞浓度、延长治疗暴露，并减少系统性毒性和对预处理淋巴清除化疗的依赖。 BrainChild-03一期已经证明这种模式具有实际可行性：21名DIPG患者累计接受253次输注，最高单次达到1亿个CAR-T细胞，说明“长期重复脑内给药”并非纯粹概念。第二，多靶点CAR设计解决实体瘤最典型的抗原逃逸问题。脑瘤并不像CD19阳性白血病那样拥有相对统一的靶点，同一肿瘤内部不同细胞可能分别表达EGFR、HER2、B7-H3或IL13Rα2。只攻击一个靶点容易筛选出抗原阴性的耐药克隆。因此公司正在从单靶点BCB-276升级到BCB-214的EGFR+B7-H3+IL13Rα2三靶点设计，本质上是扩大肿瘤覆盖率、降低抗原逃逸概率。其技术基础也并非完全从零开始，上述多个CAR靶点已有Seattle Children’s临床研究经验。第三，“Functional Retention”试图解决CAR-T进入肿瘤后失活的问题。 GBM等脑瘤微环境具有强烈免疫抑制作用，可导致T细胞耗竭、迁移不足和持续性下降。 BrainChild称其建立了一组可与CAR共同表达的合成转基因，用于维持T细胞抗肿瘤功能，BCB-214将整合这些技术。近期研究也显示，通过增强CXCR3-A表达可以改善B7-H3 CAR-T向DIPG肿瘤迁移并提高动物模型疗效，说明“主动工程化改善CAR-T迁移/功能”具有一定生物学依据。从科学投资角度看公司真正有价值的不是单一B7-H3 CAR-T，而是“局部递送+重复给药+多靶点+功能增强”这一组合式CNS细胞治疗平台。如果BCB-276能够在人体验证显著生存获益，后续BCB-214进入GBM就具有较强的平台外推逻辑。但风险同样明显 1、三靶点和附加转基因会增加制造及质量控制复杂度； 2、脑室导管和反复输注降低治疗便利性； 3、更关键的是，目前“功能增强”和多靶点优势仍主要处于早期临床或临床前验证阶段。因此，BrainChild的科学逻辑较强、工程设计有针对性，但平台价值能否真正成立，最终仍要看BCB-276的确证性生存数据以及BCB-214能否在高度异质的GBM中复制疗效。 BrainChild Bio的Pipeline BrainChild Bio目前公开Pipeline并不复杂，核心只有两个项目，但结构非常清晰：BCB-276负责验证技术与监管路径，BCB-214负责验证平台能否扩展到更大的脑肿瘤市场。公司战略是先从儿童DIPG切入，再延伸至儿童DMG、成人胶质母细胞瘤（GBM）及脑转移。 1. BCB-276：决定近期公司价值的核心资产。 BCB-276是一款靶向B7-H3的自体CAR-T，用于DIPG。公司称B7-H3在DIPG中高度广泛表达，使其相比高度异质的GBM更适合作为单靶点CAR-T的首个验证适应症。更重要的是，它已从探索性项目进入关键性注册开发阶段：ILLUMINATE被设计为支持未来BLA申报的关键研究，此前公司已与FDA就开发路径达成沟通，并获得Breakthrough Therapy及RMAT资格。其投资价值来自已有的人体概念验证。BCB-276源自Seattle Children’s的B7-H3 CAR-T项目，Phase 1中21名DIPG患者从诊断起中位生存期为19.8个月，并出现超过44个月的长期生存者。不过这些数据来自早期、单中心、非随机研究，因此目前仍应视为强烈疗效信号，而非确证性证据。 2. BCB-214：真正决定平台长期上限。 BCB-214是下一代三靶点CAR-T，同时针对EGFR、B7-H3和IL13Rα2，主要面向GBM，同时计划覆盖DMG。其设计逻辑明显比BCB-276更复杂：GBM内部抗原高度异质，单靶点治疗容易产生抗原逃逸，因此同时攻击三个靶点有望扩大肿瘤细胞覆盖率。 BCB-214还整合公司的Functional Retention技术和重复脑室内给药。前者通过合成转基因维持CAR-T在免疫抑制微环境中的功能，后者直接向脑室输注，以提高CNS内肿瘤暴露。因此它实际上是BrainChild全部技术模块——多靶点、功能增强和局部递送——第一次真正组合到一个产品中。 3. Pipeline结构的最大优势是“由小市场验证、向大市场扩张”。 DIPG在美国患者数量有限，但疾病严重、治疗选择少、临床终点明确，因此非常适合作为技术和监管验证入口；一旦BCB-276成功，公司即可把临床、制造和局部给药经验迁移到GBM。公司称GBM美国每年约1.5万例，而脑转移涉及更庞大患者群，因此商业潜力主要来自后续扩张，而不是DIPG本身。 BrainChild的Pipeline属于典型的“单靶点产品去风险→多靶点平台放大价值”模式。BCB-276决定未来数年的临床和监管成败，BCB-214决定公司能否从一家罕见儿童脑瘤公司升级为CNS肿瘤细胞治疗平台。主要风险包括BCB-276疗效能否在关键试验复制，以及BCB-214三靶点、功能增强、自体制造和反复脑内给药叠加后带来的安全性、CMC和商业化复杂度。欲深入了解更多行业洞察，请扫以下二维码加入社群：公司已完成项目星际微光已完成的项目（截至2023.9，仍在继续......）圆满中秋 | 星际微光七年完成100个咨询项目咨询、调研、PR、投资、融资、营销、技术转化项目需求请扫码联系我们：点击“阅读原文”，看看：首个搭载生成式 AI 视频编辑的无反相机系统！

2026-09-10

·Firstwordpharma

BrainChild Bio moves CAR-T into pivotal study for paediatric brain cancer

With $116 million in new funding on tap, BrainChild Bio said Tuesday that it has initiated a pivotal study of the B7-H3-targeted autologous CAR-T cell therapy BCB-276, in the hopes of delivering a much-needed new treatment option for patients with diffuse intrinsic pontine glioma (DIPG). With the current standard-of-care treatment for DIPG limited to palliative focal radiation therapy, median overall survival for this rare and aggressive paediatric brainstem tumour is about 11 months from diagnosis. In the Phase I BrainChild-03 study, BCB-276 has already bettered this, boosting median survival from diagnosis in 21 patients — including those treated both before and after disease progression — to 19.8 months. CEO Steven Brugger told FirstWord that in the subset of pre-progression patients in the early-stage study, there are three who have survived more than 5 years post-diagnosis. "Such long-term survivors are unheard of in DIPG." BrainChild Bio is now hoping to replicate this result in a larger Phase II trial, which is designed to recruit 75 children and young adults with newly diagnosed DIPG who will all be administered BCB-276 following initial focal radiation therapy. The ILLUMINATE study will compare the patients' outcomes — looking at overall survival, safety and tumour response — to those from similar individuals with DIPG whose data have been collected in a registry. The trial, based on discussions with the FDA, is designed to speed the path to submitting a marketing application for BCB-276 in the US. According to an entry on ClinicalTrials.gov, the study has an estimated primary completion date of late 2028. The alignment with the FDA has allowed the company to swiftly move forward with development, despite slight differences between the CAR-Ts being used in the two trials. Brugger explained to FirstWord that the therapy studied in Phase I "is very similar" to BCB-276, but the latter has been optimised for the pivotal trial. "The optimisation primarily related to features that streamline the manufacturing of BCB-276," Brugger said, noting that "in our meetings with the FDA, they agreed that we can seamlessly transition from the CAR-T therapy used in Phase I to the BCB-276 in Phase II." Last year, BrainChild Bio entered a collaboration with contract development and manufacturing organisation OmniaBio on production of BCB-276. The CAR-T is produced from a participant's own immune cells, with the treatment administered by locoregional delivery directly into the cerebrospinal fluid using an indwelling reservoir-catheter device. In ILLUMINATE, patients will receive the CAR-T therapy approximately every two weeks for a planned course of up to a total of 15 doses over about 7-8 months. Brugger noted that the delivery method allows BCB-276 to be "applied more like a drug, with a controlled, repetitive dosing regimen," whilst also taking advantage of the blood-brain barrier to contain the CAR-T within the brain and avoid any off-target effects. The localised dosing of BCB-276 also removes the need for lymphodepleting chemotherapy, and its associated risks of cytokine and inflammatory responses, an issue seen with traditional CAR-T therapies. BrainChild Bio has moved swiftly since its launch in 2023 to further the work of Michael Jensen at Seattle Children's hospital into CAR-T therapies for CNS tumours. "Bringing this pivotal Phase II study forward for children battling DIPG has been our steadfast purpose at BrainChild Bio," said Jensen, who serves as the biotech's chief scientific officer. The mid-stage trial will be funded with proceeds from the series A financing, which closed Tuesday, with backing from BrainChild Bio's initial investor, Seattle Children's, and new participant WRF Capital. However, the funding round was led by an undisclosed private family fund and foundation, which is aligned with the biotech's mission. While this mission is initially taking aim at DIPG, BrainChild Bio harbours ambitions beyond this via its second pipeline asset, a triple-targeting CAR-T therapy dubbed BCB-214. The compound takes aim at EGFR, B7-H3 and IL13Ralpha2 in an effort to treat glioblastoma in adults, as well as other paediatric brain tumours, such as diffuse midline glioma. The content above comes from the network. if any infringement, please contact us to modify.

免疫疗法细胞疗法

2026-09-10

·BioPharmaDive

BrainChild hauls in $116M to make cell therapies for childhood brain cancers

BrainChild Bio, a cell therapy developer making CAR-T treatments for children with rare brain cancers, has banked $116 million in a round of venture financing, the company announced Tuesday.CAR-T therapies are powerful treatments engineered from immune cells. A handful have been approved to treat certain blood cancers, and many companies are studying their potential on other tumorsand even autoimmune diseases.But according to BrainChild founder and Chief Scientific Officer Michael Jensen, few companies have tried to test CAR-T treatments against brain cancer.The prejudice is that the brain would be intolerant to having cells directly administered, he said.BrainChild is different. Spun out of research at Seattle Childrens Hospital three years ago, the company is working on a pair of brain cancer cell therapies designed specifically for children.Focusing on kids isnt typical for up-and-coming biotech companies, as the sales opportunities in uncommon childhood cancers pale in comparison to the larger markets for many malignancies afflicting adults.Yet BrainChild has already made considerable progress.One treatment, called BCB-276, is in Phase 2 testing in a rare and deadly brain stem tumor called diffuse intrinsic pontine glioma. Another, BCB-214, is in preclinical development for glioblastoma and is poised to start human testing next year, according to CEO Steven Brugger.Financing pediatric programs is and has always been more challenging, Brugger said. While I understand the business we're in, it is still so very disappointing to me and [Jensen], and especially for these patients and their families.Diffuse intrinsic pontine glioma, or DIPG, affects an estimated 300 children in the U.S. each year, according to the National Cancer Institute. Those tumors are usually treated with radiation, chemotherapy, and in some cases a surgical procedure that funnels fluid away from the brain. But most afflicted children die within two years of their diagnosis.BCB-276 targets a protein called B7-H3 thats overexpressed on a wide range of tumors, among them DIPG. Notably, recipients dont have to get a chemotherapy conditioning regimen prior to treatment, as is usually the case with CAR-T therapies. That distinction enables BrainChild to envision administering multiple doses of its treatment. It also helps keep the re-engineered cells in the brain, which could lower the risk of systemic side effects such as a hyperactive immune response called cytokine release syndrome.The blood-brain barrier is our ally, Jensen said.The ongoing Phase 2 study has a primary completion date in 2028, according to a federal database.Behind BCB-276 is an experimental treatment called BCB-214. That treatment is designed to go after B7-H3 as well as two other targets overexpressed in glioblastoma, one of the most common and fatal forms of brain cancer. Jensen said the treatment has certain components that help the souped-up cells function in an immunosuppressive environment in and around glioblastomas.Investors in BrainChilds Series A round include Seattle Childrens and the venture arm of the Washington Research Foundation. An unnamed private family fund and foundation led the financing. '

临床2期细胞疗法免疫疗法

100 项与 BCB-214 相关的药物交易

登录后查看更多信息